Skye Bioscience, Inc. Common Stock
SKYESkye Bioscience, Inc. (SKYE) is a biotechnology company focused on developing cannabinoid-based pharmaceutical products. The company aims to leverage its proprietary formulations and delivery technologies to create targeted therapies for various medical conditions, including glaucoma and other ophthalmic diseases. Skye Bioscience focuses on advancing innovative treatments that utilize cannabinoids to address unmet medical needs.
Company News
Levi & Korsinsky has filed a securities class action lawsuit against Skye Bioscience, Inc. on behalf of shareholders who suffered losses between November 4, 2024 and October 3, 2025. The complaint alleges that defendants made false statements about the effectiveness of the company's lead product candidate, nimacimab, and overstated its clinical, ...
Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstat...
Rosen Law Firm is reminding investors in Jayud Global Logistics Ltd. (JYD), Skye Bioscience, Inc. (SKYE), and Klarna Group plc (KLAR) of upcoming lead plaintiff deadlines in securities class action lawsuits. The firm is encouraging affected investors to secure legal counsel to potentially recover losses from alleged fraudulent activities and misl...
Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. Th...
Rosen Law Firm is reminding investors in Skye Bioscience, Inc. (NASDAQ: SKYE) of the January 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects, ca...
